Proteomic approaches to tumor marker discovery: Identification of biomarkers for ovarian cancer

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 12, 2002, Pages 1518-1526

  Rai, Alex J ^a   Zhang, Zhen ^a   Rosenzweig, Jason ^a   Shih, Le ming ^a   Pham, Thang ^b   Fung, Eric T ^b   Sokoll, Lori J ^a   Chan, Daniel W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; TUMOR MARKER;

ADULT; AGED; BIOINFORMATICS; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER SCREENING; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0037000528     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Banks E, Beral V, Reeves G. The epidemiology of epithelial ovarian cancer: a review. Int J Gynecol Cancer. 1997;7:425-438.
2. Parkin DM, Muir CS, Whelan SF. Cancer Incidence in Five Continents. Lyon, France: IARC Scientific; 1992.
3. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-37.
4. Paley PJ. Ovarian cancer screening: are we making any progress? Curr Opin Oncol. 2001;13:399-402.
5. Ozols RF, Rubin SC, Thomas GB, Robboy SI. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. 3rd ed. Philadelphia, Pa: Lippincott, Williams and Wilkins; 2000:981-1057.
6. MacDonald ND, Jacobs IJ. Is there a place for screening in ovarian cancer? Eur J Obstet Gynecol Reprod Biol. 1999;82:155-157.
7. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1-12.
8. Shih I-M, Sokoll LJ, Chan DW. Tumor markers in ovarian cancer. In: Diamandis EP, Fritsche H, Lilja H, Chan DW, Schwartz M, eds. Tumor Markers Physiology, Pathobiology, Technology and Clinical Applications. Philadelphia, Pa: AACC Press; 2002:239-252.
9. Woolas RP XF, Jacobs IJ, Yu YH, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993;85:1748-1751.
10. Woolas RP, Conaway MR, Xu F, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol. 1995;59:111-116.
11. Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol. 1999;73:56-61.
12. Zhang Z, Xu F, Yu Y, Berchuck A, et al. Use of multiple markers to detect stage I epithelial ovarian cancers: neural network analysis improves performance. Presented at: Annual Meeting of the American Society of Clinical Oncology; May 12-15 2001; San Francisco, Calif. Abstract 873.
13. Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(suppl):2004-2010.
14. Jacobs I, Davies AP, Bridges J, Stabile I, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993;306:1030-1034.
15. Menon U, Talaat A, Rosenthal AN, Macdonald ND, et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. Br J Obstet Gynaecol. 2000;107:165-169.
16. Bast RC, Jr, Urban N, Shrindhar V, et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res. 2002;107:61-97.
17. Bichsel VE, Liotta LA, Petricoin EF 3rd. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J. 2001;7:69-78.
18. Velculescu VE, Vogelstein B, KinzIer KW. Analysing uncharted transcriptomes with SAGE. Trends Genet. 2000;16:423-425.
19. Schaefer C, Grouse L, Buetow K, Strausberg RL. A new cancer genome anatomy project web resource for the community. Cancer J. 2001;7:52-60.
20. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol. 2001;158:1491-1502.
21. Banks RE, Dunn MJ, Forbes MA, et al. The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis - preliminary findings. Electrophoresis. 1999;20:689-700.
22. Paweletz CP, Gillespie JW, Ornstein DK, et al. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev Res. 2000;49:34-42.
23. von Eggeling F, Junker K, Fiedler W, et al. Mass spectrometry meets chip technology: a new proteomic tool in cancer research? Electrophoresis. 2001;22:2898-2902.
24. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Electrophoresis. 2000;21:1164-1177.
25. Weinberger SR, Morris TS, Pawlak M. Recent trends in protein biochip technology. Pharmacogenomics. 2000;1:395-416.
26. Palmer-Toy D, Kuzdzal S, Chan, DW. Proteomic approaches to tumor marker discovery. In: Diamandis EP, Fritsche H, Lilja H, Chan DW, Schwartz M, eds. Tumor Markers Physiology, Pathobiology, Technology and Clinical Applications. Philadelphia, Pa: AACC Press; 2002:391-400.
27. Fung ET, Thulasiraman V, Weinberger SR, Dalmasso EA. Protein biochips for differential profiling. Curr Opin Biotechnol. 2001;12:65-69.
28. Fung ET, Wright GL Jr, Dalmasso EA. Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther. 2000;2:643-650.
29. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Monterey, Calif: Wadsworths & Brooks; 1984.
30. Zhang Z, Page G, Zhang H. Applying classification separability analysis to microarray data. In: Lin SM, Johnson KF, eds. Methods of Microarray Data Analysis: Papers From CAMDA '00. Boston, Mass: Kluwer Academic Publishers; 2001.
31. Vapnik VN. Statistical Learning Theory. New York, NY: John Wiley & Sons; 1998.
32. Brown M, Grundy WN, Lin D, et al. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci U S A. 2000;97:262-267.
33. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535-1538.
34. Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75:264-265.
35. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215-245.
36. Werness BA, Eltabbakh GH. Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features. Int J Gynecol Pathol. 2001;20:48-63.
37. Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1999:477-540.
38. SAGE (Serial Analysis of Gene Expression) home page. Available at: http://www.sagenet.org. Accessed August 6, 2002.
39. Tusher VG TRaCG. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121.